HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation
Autor: | Diego Rincón, Aránzazu Caballero-Marcos, Ainhoa Fernández-Yunquera, Lucia Dieguez, Cristina Navarrete, Ana Clemente, Rafael Bañares Cañizares, Magdalena Salcedo, Mario Romero-Cristóbal, Marta Puerto, Fernando Diaz-Fontenla, Pilar Catalán, José-Ángel López-Baena |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Hepatitis C virus medicine.medical_treatment Hepacivirus macromolecular substances Liver transplantation medicine.disease_cause DIRECT ACTING ANTIVIRALS Antiviral Agents Gastroenterology Endothelial activation Internal medicine medicine Humans Endothelial dysfunction Recurrent hepatitis Transplantation business.industry virus diseases Hepatitis C Hepatitis C Chronic medicine.disease digestive system diseases Liver Transplantation Increased risk business |
Zdroj: | Transplant International. 34:2214-2225 |
ISSN: | 1432-2277 0934-0874 |
Popis: | The increased risk of cardiovascular disease (CVD) conferred by hepatitis C virus (HCV) is especially relevant after liver transplantation (LT), but its mechanism is still not well defined. This study aimed to evaluate the influence of HCV eradication in inflammatory and endothelial activation markers after LT. We evaluated inflammatory (TNF-alfa, IL-6, IL-8, and MCP-1) and endothelial activation (E-selectin, ICAM-1, VCAM-1, and MMP-9) markers before and after eradication in 45 LT recipients with HCV infection (LT+/HCV+) and 44 non-transplanted HCV-infected patients (LT-/HCV+). We also considered an additional group of 40 LT recipients without HCV infection (LT+/HCV-). LT+/HCV+ patients presented a higher endothelial activation status before eradication compared with LT+/HCV- patients. However, levels of E-selectin, ICAM-1, VCAM-1, and MMP-9 were comparable between LT+/HCV+ and LT-/HCV+ patients before eradication. HCV eradication decreased ICAM-1 (5466.55 pg/ml vs. 3354.88 pg/ml, P |
Databáze: | OpenAIRE |
Externí odkaz: |